Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM)  is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It increased its price objective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 to $41. The company’s Alpha-1 Antitrypsin Deficiency program received a favorable regulatory update before the change. The latest regulatory action was Bernstein ...